194804-75-6 Usage
Description
Garenoxacin, also known by its brand name Geninax, is a novel quinolone antimicrobial agent that demonstrates a broad spectrum of activity against both Gram-negative and Gram-positive organisms. It is particularly effective against community-acquired respiratory pathogens such as S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Garenoxacin also exhibits potent activity against resistant strains, including multidrug-resistant S. pneumoniae, methicillin-resistant S. aureus (MRSA), and vancomycin-resistant enterococci (VRE). The mechanism of action involves dual inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV. It was launched in Japan as an oral treatment for respiratory tract and otorhinolaryngological infections.
Uses
Used in Pharmaceutical Industry:
Garenoxacin is used as an antibacterial agent for treating respiratory tract and otorhinolaryngological infections. Its broad-spectrum activity and potent action against resistant strains make it a valuable addition to the arsenal of antibiotics for combating bacterial infections.
Used in Research and Development:
Garenoxacin is used as a topoisomerase II inhibitor in the study of bacterial DNA replication and the development of new antimicrobial agents. Its dual inhibition of DNA gyrase and topoisomerase IV provides insights into the mechanisms of bacterial resistance and the design of more effective antibiotics.
Used in Clinical Trials:
Garenoxacin is used as a test subject in clinical trials to evaluate its safety, efficacy, and pharmacokinetics in treating various bacterial infections. The data obtained from these trials contribute to the understanding of its potential benefits and risks, as well as its optimal dosage and administration.
Used in Drug Resistance Studies:
Garenoxacin is used in research to investigate the mechanisms of bacterial resistance to quinolone antibiotics. Understanding these resistance mechanisms can help in the development of strategies to overcome resistance and improve the effectiveness of garenoxacin and other quinolone antibiotics.
Check Digit Verification of cas no
The CAS Registry Mumber 194804-75-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,4,8,0 and 4 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 194804-75:
(8*1)+(7*9)+(6*4)+(5*8)+(4*0)+(3*4)+(2*7)+(1*5)=166
166 % 10 = 6
So 194804-75-6 is a valid CAS Registry Number.
InChI:InChI=1/C23H20F2N2O4.CH4O3S/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30;1-5(2,3)4/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30);1H3,(H,2,3,4)/t11-;/m1./s1
194804-75-6Relevant articles and documents
Preparation method for garenoxacin and intermediate thereof
-
Paragraph 0043; 0044; 0045; 0046; 0047; 0048, (2017/07/20)
The invention provides a preparation method for garenoxacin and an intermediate thereof. The preparation method comprises the following steps: with a compound 5 as a raw material, reacting the compound 5 with bis(pinacolato)diboron or triisopropyl borate so as to obtain a compound 4; separately adding 7-bromo-1-cyclopropyl-8-difluoromethoxy-1,4-dihydro-4-oxoquinoline-3-ethyl carboxylate, a palladium catalyst and inorganic aqueous alkali and carrying out a reaction so as to obtain a compound 3; and subjecting the compound 3 to hydrolysis and a reduction reaction so as to obtain a compound 2 and garenoxacin (a compound 1). The compound 3 has excellent stability; raw materials for preparation of garenoxacin are cheap and easily available; reaction operation is simple; yield is high; litter waste gas, waste water and industrial residue are produced; and thus, the preparation method has good industrial prospects.
